According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.

A pilot test used a novel therapy was able to permanently reduce LDL cholesterol and triglyceride levels by turning off a ...

Labshares is leasing nearly 58,000 square feet in Watertown, more than doubling its footprint to over 100,000 square feet of ...

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...

Only one in every six million people have the Rh null blood type. Now researchers are trying to grow it in the laboratory in ...

The N-glycans attached to the Fc region of immunoglobulin G (IgG) contain combinations of core fucose, bisecting GlcNAc, galactose, and sialic acid; variations in these monosaccharides - regulated ...

Q3 2025 Management View President & COO Joseph Hazelton highlighted a pivotal shift, stating Dyadic is now operating as a “commercially focused biotechnology company with a growing portfolio of ...

A U.S. biological research institute has developed a new genetic modification technique that promises a wide range of organism mutations while being safer than the ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...